Genvoya Dosage

Testing Prior to Initiation and During Treatment with GENVOYA

Prior to initiation of GENVOYA, patients should be tested for hepatitis B virus infection [see Warnings and Precautions (5.1)].

​Prior to and during treatment, as clinically appropriate, assess serum creatinine, estimated creatinine clearance, urine glucose and urine protein in all patients, and also assess serum phosphorus in patients with chronic kidney disease [see Warnings and Precautions (5.4)].

Recommended Dosage

​GENVOYA is a four-drug fixed dose combination product containing 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamide (TAF). The recommended dosage of GENVOYA is one tablet taken orally once daily with food in adults and pediatric patients with body weight at least 25 kg and creatinine clearance greater than or equal to 30 mL per minute [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

Not Recommended in Patients with Severe Renal Impairment

GENVOYA is not recommended in patients with estimated creatinine clearance below 30 mL per minute [see Use in Specific Populations (8.6)].

Not Recommended in Patients with Severe Hepatic Impairment

GENVOYA is not recommended in patients with severe hepatic impairment (Child-Pugh Class C) [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].